Karyopharm gets bump as FDA extends review of selinexor

Karyopharm gets bump as FDA extends review of selinexor

Submitted by admin on March 15, 2019 - 10:42am
Source: 
BioCentury
News Tags: 
Karyopharm
FDA
Selinexor
Multiple Myeloma
Headline: 
Karyopharm gets bump as FDA extends review of selinexor
snippet: 

Karyopharm gained 19% in morning trading Friday after it said FDA has extended by three months its review of selinexor, which is under Priority Review to treat multiple myeloma. Its PDUFA date is now July 6.

Do Not Allow Advertisers to Use My Personal information